SMS Pharmaceuticals' Q1 FY 2025-26 Quarter Results

Result Summary

• SMS Pharmaceuticals Ltd reported a 20.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 18.6%.
• Its expenses for the quarter were down by 23.7% QoQ and up 19.6% YoY.
• The net profit increased 18.6% QoQ and increased 24.3% YoY.
• The earnings per share (EPS) of SMS Pharmaceuticals Ltd stood at 2.3 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

SMS Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, known for manufacturing and marketing a wide range of pharmaceutical products. The company specializes in the production of active pharmaceutical ingredients (APIs) and has established a significant presence in both domestic and international markets. While specific recent major developments are not provided in the data, SMS Pharmaceuticals Ltd has historically focused on expanding its product portfolio and enhancing its manufacturing capabilities to meet the growing demand in the healthcare sector. The pharmaceutical industry is characterized by its high regulations, ongoing research and development activities, and a focus on innovation, which are crucial for maintaining competitiveness and ensuring product efficacy and safety.

Revenue

In Q1FY26, SMS Pharmaceuticals Ltd reported a total income of ₹196.64 crores, reflecting a year-over-year (YoY) growth of 18.6% compared to ₹165.82 crores in Q1FY25. However, the quarter-over-quarter (QoQ) comparison shows a decline of 20.5% from Q4FY25, where the total income was ₹247.44 crores. This fluctuation in revenue is indicative of a dynamic business environment, potentially influenced by factors such as market demand, pricing strategies, and production capabilities. The company's ability to achieve YoY growth suggests an increase in sales or improved market conditions over the past year, despite the quarterly decline.

Profitability

The profitability of SMS Pharmaceuticals Ltd has shown positive trends in Q1FY26. The profit before tax (PBT) for this quarter was ₹24.37 crores, marking a 12.1% increase from Q4FY25's PBT of ₹21.74 crores and an 11.6% rise from ₹21.83 crores in Q1FY25. After accounting for tax expenses, the profit after tax (PAT) reached ₹20.49 crores in Q1FY26, which is an 18.6% increase QoQ and a 24.3% increase YoY from the ₹16.48 crores in Q1FY25. These figures indicate that the company has managed to improve its profitability margins despite variations in revenue, potentially through cost management or efficiency improvements in its operations.

Operating Metrics

The total expenses for SMS Pharmaceuticals Ltd in Q1FY26 amounted to ₹172.27 crores, which represents a 23.7% decrease from ₹225.71 crores in Q4FY25, and a 19.6% increase from ₹143.99 crores in Q1FY25. This reduction in expenses QoQ may have contributed to the improved profit margins during this period. Additionally, the earnings per share (EPS) for Q1FY26 was reported at ₹2.30, showing a 15.0% increase from the previous quarter's EPS of ₹2.00 and a 21.1% increase YoY from ₹1.90 in Q1FY25. These metrics reflect the company's operational efficiency and its ability to generate higher earnings per unit of shareholder investment, which is a key indicator of financial health and operational performance.